The AI that writes the paperwork behind new medicines - so the humans can decide what actually matters.
Here is a fact about drug development that nobody puts on a poster: a huge share of the time between "we have a promising molecule" and "a patient can take it" is spent not on science, but on documents. Thousands of pages of them, formatted to an exacting standard called eCTD, cross-referenced against source data, and re-checked by people who would rather be doing almost anything else. Weave Bio's entire premise is that this part - the paperwork - is an engineering problem.
The company, legally Weave Platform, Inc., was founded in 2022 in San Francisco and describes itself as "AI-native," which in 2026 is a phrase that means everything and nothing. In Weave's case it means something specific: the platform reads your preclinical and clinical study data and drafts the regulatory documents - the Investigational New Drug application, the investigator's brochure, the clinical study report - in submission-ready form. A human reviews, edits, and signs off. The claim is that this compresses timelines by more than 50%. In one pharma project, Weave says its technology drafted in roughly three hours what would have taken a human team about a hundred.
You should be a little skeptical of every number a startup gives you, and Weave is a startup - it reported around $880,000 in annual revenue at the time of its Series A, which is to say it is early. But the interesting thing about Weave is not the demo. It is who is willing to stand next to it. Parexel, one of the largest contract research organizations on the planet, announced an AI partnership with this roughly 53-person company. Large CROs do not partner with strangers on the workflow that is, functionally, their entire reason to exist. That is the tell.
The founders are not tourists. Co-founder and CTO Umut Eser has a Stanford PhD in applied physics and did a postdoctoral fellowship at Harvard Medical School in genetics and computational biology; before Weave he ran machine learning at Cellarity. Co-founder Brandon Rice - the founding CEO, now Chief Product Officer - is the one who has spent his time inside the regulatory pain the product is designed to remove. That pairing, deep AI research plus deep empathy for the user, shows up in the product's most quoted design decision.
A customer put it this way: "Other AI platforms change everything. This changed only what I asked." In an unregulated consumer app, an AI that rewrites your whole document is a feature. In a regulated submission where every sentence may be audited, it is a liability. Weave's restraint - do what the user asked, and nothing else, and let them trace any generated line back to its source in two clicks - is the actual product. The generation is table stakes. The trust is the moat.
"Other AI platforms change everything. This changed only what I asked."- CEO of a small biotech customer
Regulatory timelines overall: Weave claims 50%+ acceleration. Figures are company-reported and approximate.
The core AI-native workspace: eCTD-formatted templates, document authoring, real-time collaboration with comments and version control, publishing, and two-click source traceability across programs and modalities.
Since 2022Automated preparation of preclinical Investigational New Drug (IND) submissions - the module that drafted ~100 hours of work in ~3 and earned "Biotech AI Innovation of the Year."
2024Assembles and formats complete eCTD submissions ready for FDA, EMA and other global authorities - the last mile between a draft and a filing.
2025AI and workflow automation for responding to Health Authority Questions during review - extending Weave past submission prep into the part of the process that used to mean all-nighters.
2025The product mind who lived the regulatory pain Weave removes. Regular podcast voice on AI-driven IND submission and the human-in-the-loop philosophy.
Stanford applied-physics PhD, Harvard Medical School genetics fellow, former Head of ML at Cellarity. Owns Weave's technical and AI vision.
Brandon Rice and Umut Eser start Weave Platform, Inc. in San Francisco to attack regulatory friction in drug development with AI.
Preclinical IND automation is adopted and named "Biotech AI Innovation of the Year."
The global CRO partners with Weave to accelerate regulatory submission processes.
USVP leads the round; total funding reaches roughly $36M. Expansion planned into Europe, Japan and Latin America.
Automation extends into the health-authority-question review phase.
Led by USVP, with Innovation Endeavors, Magnetic Ventures, Character, TMV and Serrado Capital. Brings total funding to about $36M. Earmarked for global expansion and a bigger commercial team.
Used by biotech, pharma, CROs and consultants - named names include Recursion, Argenx, Cartherics, Cadenza, Shattuck Labs, Cyclarity and Trace Biosciences, plus the Parexel partnership.